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Collection of airway calibre and b2-agonist data in large clinical trials and epidemiological surveys is sometimes
dicult and may be an inecient use of resources. The aim of this study was to determine whether the omission of
the forced expiratory volume in 1 sec (FEV1) and b2-agonist questions from the seven-item Asthma Control
Questionnaire (ACQ) alters its measurement properties and validity.
In an observational study, 50 adults with symptomatic asthma attended the clinic at 0, 1, 5 and 9 weeks to
complete the ACQ and other measures of asthma status.
All patients completed the study and provided complete data sets. Omission of the FEV1 and b2-agonist
questions from the ACQ made minimal difference to the reliability, responsiveness, and both cross-sectional and
longitudinal validity of the instrument. Omission of the FEV1 question significantly lowered the summary score
(P50?0001) but omission of the b2-agonist question did not alter it (P40?05).
In group studies, both the FEV1 and b2-agonist questions may be omitted from the ACQ without changing the
validity or the measurement properties of the instrument. Lowering of the summary score by the omission of the
FEV1 question means that data from this abbreviated form cannot be combined with or compared to data collected
using the full questionnaire.
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The Asthma Control Questionnaire (ACQ) was developed
and validated to measure the clinical status both of patients
participating in research studies and those being seen as
individuals in clinical practice (1). It has seven questions
covering all the criteria (symptoms, airway calibre and
rescue b2-agonist use) deemed necessary by international
guidelines committees for determining the adequacy of
asthma control (2–5).
To improve eciency, simplify data collection and reduce
costs in large clinical trials and epidemiological surveys, it
would be convenient if the questions concerning airway
calibre and rescue b2-agonist use could be omitted. In
addition, in some multi-national studies, estimates of airway
calibre and inhaled b2-agonist use are not available. The aim
of this analysis was to determine whether the questionsReceived 9 October 2000 and accepted in revised form 2 January
2001.
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from the ACQ for large studies without altering the validity
and the measurement properties of the instrument.
Methods
The database for this analysis was generated during the
validation of the ACQ (1). In brief, 50 adults (17–70 years)
with current symptoms of asthma were enrolled in a
9-week, observational study, with clinic visits at enrollment
and after 1, 5 and 9 weeks. At each visit, prebronchodilator
spirometry was measured and patients completed the ACQ,
the self-administered version of the Asthma Quality of Life
Questionnaire (AQLQ) (6) and the Medical Outcomes
Survey Short Form-36 (SF-36) (7). In addition, patients
scored five asthma symptoms that had not been selected for
the ACQ (1). For 1 week before each clinic visit, patients
recorded prebronchodilator peak expiratory flow (PEF)
each morning. At each follow-up visit, a clinician rated
change in the patient’s asthma control since the previous
clinic visit (7=a very great deal better, 0=no change,
77=a very great deal worse) (8). The clinician was blinded
to the ACQ data and used only spirometry, diary, AQLQ# 2001 HARCOURT PUBLISHERS LTD
TABLE 1. Patient characteristics
Number 50
Gender (M/F) 18/32
Age (mean : SD) 37?1 : 13?1
FEV1% predicted pre-BD (mean : SD) 77?2 : 18?8
PEF (mean : SD) 406?3 : 107?5
Medication use
(a) Short-acting b2-agonists alone 12
(b) Inhaled steroids  (a) 34
(c) Long-acting b2-agonist  (b) 3
(d) Oral steroids + (c) 1
TABLE 2. Questionnaire scores at the end of week 1
Mean+SD
All questions 1?49+0?66
Symptoms alone
Nocturnal waking
Morning symptoms
Activity limitation
Short of breath
Wheeze
1?23+0?59
0?58+1?03
1?28+0?95
1?26+1?16
1?70+0?91
1?34+0?77
SymptomsFEV1 1?47+0?67
Symptoms  b2-agonist use 1?29+0?72
320 E. F. JUNIPER ET AL.and SF-36 data plus a consultation with the patient. The
study was approved by the McMaster University Faculty of
Health Sciences Ethics Committee. All patients signed an
informed consent.
ASTHMA CONTROL QUESTIONNAIRE
The development and validation of the ACQ is described in
detail elsewhere (1). The ACQ contains seven questions, five
of which concern symptoms and activity limitations, one on
FEV1% predicted and one on short-acting b2-agonist use.
Patients are asked to recall their symptoms and b2-agonist
use during the previous week. FEV1% predicted is the value
recorded in the clinic at the time the questionnaire is
completed. All seven questions are scored on a 7-point scale
(0=good control, 6=poor control) and the overall score is
the mean of the seven responses.
STATISTICAL ANALYSIS
The aims of the statistical analysis were to determine
whether the abbreviated instruments are valid measures of
asthma control and to compare their measurement proper-
ties with those of the original ACQ.
Differences in scores between the complete seven-item
ACQ and the three abbreviated versions (symptoms alone,
symptoms plus FEV1 and symptoms plus b2-agonist use)
were examined using a paired t-test. Pearson correlation
coecients were used to examine associations between the
ACQ and the abbreviated versions. As described in detail
elsewhere (1), testing the measurement properties of the
instruments required defining a group of patients who
remained clinically stable between clinic visits (weeks 1–5
and weeks 5–9) and another group who experienced change
in their asthma control. For each time period, we
categorized each patient using the clinician’s global rating
of change: stable group = scores of 71, 0 or 1; unstable
group = scores of 77 to 72 and 2 to 7 (8).
Discriminative properties (9)
Reliability was determined from patients in the stable
group. If a patient was stable between both weeks 1–5 and
weeks 5–9, a single observation was selected using a
random number generator. Reliability was estimated as
the within-subject standard deviation and related to the
total standard deviation as an intra-class correlation
coecient (ICC). For cross-sectional validity, we used data
from the second clinic visit (week 1) and made a priori
predictions concerning the degree of correlation we should
expect with other measures of health status if the
instruments truly measure asthma control. The predictions
were based on results from previous studies.
Evaluative properties (9)
Responsiveness was examined in three ways. First, for
patients in the unstable group, we determined whether thequestionnaires could detect within-patient change using a
paired t-test. Second, we assessed whether they could detect
differences between stable and unstable patients using an
unpaired t-test. Third, we calculated the responsiveness
index (D/SDD) (10). To ensure that the contribution of two
observations by some patients did not result in an
overestimate of the precision of responsiveness, we inflated
the variance by the quantity 1(n71)r, where r is the ICC
of the change scores and n=2 (number of observations
per subject) (11). For longitudinal validity, we once again
made a priori predictions based on results from previous
studies.
Results
All 50 patients completed the study and provided complete
data sets (Table 1).
The mean scores at the end of week 1 for the ACQ and
each of the abbreviated versions are shown in Table 2.
There was no evidence of any difference in scores between
the ACQ and symptoms  FEV1 (mean=0?02; SD=0?14;
P=0?37). However, both the difference between the ACQ
and symptoms alone (mean=0?26; SD=0?37) and the
difference between the ACQ and symptoms  b2-agonist
(mean=0?20; SD=0?28) were significant (P50?0001).
Correlations between the ACQ and the abbreviated
ASTHMA CONTROL IN CLINICAL STUDIES 321versions were high; symptoms alone: r=0?87, symptoms
FEV1: r=0?98 and symptom + b2-agonist: r= 0?92.
Reliability of the ACQ (ICC=0?91) was very similar to
that of the three abbreviated versions (symptoms
FEV1=0?89; symptoms  b2-agonist=0?90; symptoms
alone=0?89). Similarly, there was no evidence of any
difference in responsiveness between the ACQ and the three
abbreviated versions (Table 3), and neither was there any
evidence of deterioration in responsiveness indices
(ACQ=1?06; symptoms FEV1=1?10; symptoms  b2-
agonist=1?20; symptoms alone=1?27). The consistency
of the standard deviations and the responsiveness indices
(Table 3) indicate that study sample sizes will be similar for
all four instruments.
Both cross-sectional and longitudinal correlations with
other measures of health status were very similar for the
ACQ and the three abbreviated versions (Tables 4 and 5).TABLE 3. Responsiveness (change in score between consecutive
Patients with stable
asthma (n=36)
mean (SD*)
All questions 0?004 (0?25)
Symptoms alone 70?01 (0?31)
Symptoms  FEV1 0?01(0?27)
Symptoms  b2-agonist use 70?01 (0?27)
n = number of observations.
*Adjusted for multiple responses.
**P50?0001.
TABLE 4. Cross-sectional validity (Pearson correlation coecien
All questions Sympto
Asthma Quality of Life Questionnaire
Overall 0?76 0
Symptoms 0?75 0
Emotions 0?66 0
Activities 0?71 0
Environment 0?55 0
Generic health status (SF-36)
Physical 0?55 0
Mental 0?18 0
Other asthma symptoms 0?42 0
A priori predictions:
(1) AQLQ: r=0?470?8. The highest correction should be with
environmental domain (r=0?4 7 0?6).
(2) Physical health domain of the SF-36: r=0?470?6.
(3) The five additional asthma control symptoms: r=0?470?6Discussion
Correlations between all three abbreviated versions (symp-
toms alone, symptoms b2-agonist use and symptoms
FEV1) and the original ACQ were high, providing
evidence that all three are measuring exactly the same
construct (concept) as the original ACQ (criterion validity).
This is further supported by the similarity of correlations,
both cross-sectional and longitudinal, with other measures
of health status (construct validity). The reliability and
responsiveness of the three abbreviated versions of the
ACQ are very similar to those of the original ACQ,
suggesting that all four questionnaires have similar abilities
to detect differences between patient groups in cross-
sectional surveys and treatment effects in clinical trials.
Thus, all three abbreviated versions are valid measures of
asthma control with strong measurement properties andclinic visits)
Patients in whom
asthma changed
(n=50)
mean (SD*)
Difference
P-value
0?73 (0?69)** 50?0001
0?88 (0?77)** 50?0001
0?77 (0?69)** 50?0001
0?81 (0?66)** 50?0001
t)
ms alone Symptoms  FEV1 Symptoms b2-agonist use
?85 0?77 0?82
?85 0?74 0?85
?68 0?65 0?70
?77 0?74 0?73
?63 0?58 0?59
?50 0?56 0?50
?29 0?14 0?32
?56 0?41 0?56
the symptom domain (r=0?670?8) and the lowest with the
.
TABLE 5. Longitudinal validity (Pearson correlation coecient)
D All questions D Symptoms
alone
D Symptoms
 FEV1
D Symptoms
 b2-agonist use
Asthma Quality of Life Questionnaire
D Overall
D Symptoms
D Emotions
D Activities
D Environment
0?77
0?79
0?64
0?69
0?34
0?77
0?79
0?62
0?68
0?34
0?76
0?77
0?63
0?68
0?33
0?78
0?81
0?63
0?68
0?35
Generic health status (SF-36)
D Physical
D Mental
0?29
0?13
0?25
0?13
0?28
0?10
0?27
0?16
D Other asthma symptoms 0?49 0?52 0?47 0?54*
A priori predictions:
(1) Change in AQLQ: r=0?470?8; the highest correlations should be with the symptom domain (r=0?670?8) and the
lowest with the environmental domain (r=0?470?6).
(2) Change in physical health domain of the SF-36: r=0?270?4.
(3) Change in the five additional asthma symptoms (cough, chest tightness, sputum, coloured sputum and clearing the throat):
r=0?470?6.
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epidemiological surveys to measure asthma control.
The inclusion/exclusion of rescue b2-agonist use makes
no difference to the summary score, whereas removal of the
FEV1 question lowers the summary score significantly. This
means that summary scores calculated without the FEV1
question are perfectly valid for measuring asthma control
but they cannot be combined or compared with summary
scores that include the FEV1 question.
For categorizing patients into the stable and unstable
groups it would have been ideal for several clinicians,
blinded to the ACQ data, to have independently assessed
each patient at each clinic visit and a consensus taken as to
whether each patient had changed. This was not feasible
and left us with the choice of reviewing recorded data at a
later date for a group decision or having one clinician make
the decision at the time of the clinic visit. We selected the
latter because a group decision would have had to rely
heavily on recorded symptoms, b2-agonist use and airway
calibre, i.e. all the data recorded in the ACQ. The approach
we took makes it less likely that spuriously high correla-
tions resulted from ACQ data exercising undue influence on
the global rating.
A limitation of this study was the relatively small sample
size (n=50) but was of a size comparable to other
questionnaire validation studies (6, 12–14). Although the
patients represented a wide range of asthma severity (Table
1), they tended to be fairly well controlled (Table 2). Since
measurement properties of valid instruments tend to be
consistent irrespective of the severity of the impairment
(6, 12–14), the results of this study should apply to patients
with more severely uncontrolled asthma. Nevertheless,
confidence in the validity of the abbreviated versions of
the ACQ will increase as they are evaluated in future studies.It is important to emphasize that the results of this study
only apply to the use of the ACQ in clinical trials and
epidemiological surveys. They should not be interpreted to
mean that spirometry and use of rescue b2-agonist may be
excluded from the estimation of asthma control in
individual patients. The reason that international guidelines
on the management of asthma identify that all three factors
(symptoms, airway calibre and rescue b2-agonist) (2–5)
should be used to evaluate asthma control in individual
patients is that there is a wide variation in the way patients
manifest inadequacy of asthma control (15). The reason
that we are able to omit the measurement of FEV1 and
b2-agonist use from the assessment of asthma control in
large studies is that the effect of patient heterogeneity is lost
in large sample sizes.
In conclusion, we have shown that asthma symptoms
alone may be used to estimate asthma control in large
studies. This will help investigators wishing to improve the
eciency of data collection in large studies and for those
who do not have access to estimates of airway calibre or
inhaled b2-agonist use.
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